Protara Therapeutics (NASDAQ: TARA) is a clinical-stage biotechnology company that develops investigational cell therapies and other drug candidates, with no approved products and no commercial revenue as of the 10-K filed 2026-03-10. The company does not generate product revenue and funds operations through capital markets activity. Its pipeline centers on TARA-002, an investigational cell therapy derived from OK-432, a broad immunopotentiator originally granted marketing approval by the Japanese Ministry of Health. Protara carries two development programs utilizing TARA-002 as of the filing date. Because the company has not commercialized any product, its financials reflect research and development expenditures, clinical trial prepaid and accrued expenses, and operating losses. Capital structure is that of a pre-revenue biotech dependent on equity financing rather than operating cash flow.

Revenue model

No product revenue reported. The company is pre-commercial and funds operations through equity issuances. No licensing, royalty, or collaboration revenue streams are described in the filing excerpts.

Products and services

TARA-002: an investigational cell therapy based on OK-432, a broad immunopotentiator originally approved by the Japanese Ministry of Health. Two development programs utilizing TARA-002 are active as of the 10-K filed 2026-03-10. No approved or commercialized products are disclosed.

Customers and end markets

No commercial customers. End markets are not yet applicable given pre-commercial stage. Clinical trial participants are the current subjects of the company's development programs.

Value-chain role

Drug developer at the clinical-stage. Relies on third-party service providers and contract research organizations for clinical trial execution, as evidenced by clinical trial prepaid and accrued expense accounting disclosed in the 2026-03-10 10-K.

Geographic exposure

Incorporated and operating in the United States. No specific geographic revenue mix disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-10

Industry: Biological Products, (No Diagnostic Substances) Peers: Aligos Therapeutics Inc Applied Molecular Transport Inc. Beyondspring Inc CASI Pharmaceuticals, Inc (DE) Cyclerion Therapeutics Inc PhaseBio Pharmaceuticals Inc Eledon Pharmaceuticals Inc Gain Therapeutics Inc Molecular Templates, Inc.